TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05535153

Intervention type: OTHER
Intervention: functional movement screen
Description: The volunteer subjects had to perform the FMS test at the request of the investigator, which is made up of seven movements: the squat, the crossing of the hurdle, the line lunge, the active elevation with the straight leg, a movement concerning the mobility of the shoulders, a rotational stability assessment movement and a core stability assessment movement.
Study: NCT05689749

Intervention type: DEVICE
Intervention: Superb Microvascular Imaging (SMI) (Toshiba)
Description: To determine whether SMI has diagnostic value for detecting the inflammatory state in the lacrimal glands in Sjögren's syndrome and whether it has any superiority compared to Power Doppler and Color Doppler modalities.

Intervention type: DEVICE
Intervention: Superb Microvascular Imaging (SMI) (Toshiba)
Description: To determine whether SMI has diagnostic value for detecting the inflammatory state in the lacrimal glands in Sjögren's syndrome and whether it has any superiority compared to Power Doppler and Color Doppler modalities.
Study: NCT05941910

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Q10
Description: 240mg of Q10 orally, every day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Q10
Description: 240mg of Q10 orally, every day
Study: NCT06534437

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glofitamab
Description: Glofitamab is a bispecific monoclonal antibody that binds bivalently to CD20 expressed on the surface of B-cells and monovalently to CD3 in the T-cell receptor complex expressed on the surface of T-cells.
Study: NCT05492201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3873862
Description: Administered orally.
Study: NCT05770739

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Perioperative accelerated rehabilitation surgical measures
Description: To apply accelerated rehabilitation surgery to children with biliary dilatation during perioperative period

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Traditional treatment
Description: To provide traditional perioperative treatment for children with cholangiectasia
Study: NCT05492201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3873862
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3873862
Description: Administered orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally.
Study: NCT05623306

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: PMT Stereoencephalography (SEEG)
Description: For Stage 1 of this study, we will be implanting depth electrodes to record stereoencephalography across a network of brain regions.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PMT Stereoencephalography (SEEG)
Description: For Stage 1 of this study, we will be implanting depth electrodes to record stereoencephalography across a network of brain regions.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Vercise Genus™ Deep Brain Stimulation (DBS) System
Description: For Stages 2 and 3 of this study, we intend to use the DBS system to treat patients with severe symptoms of chronic, treatment-refractory OCD by targeting stimulation to sites that have been determined to have therapeutic benefit during our SEEG Invasive Monitoring phase.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vercise Genus™ Deep Brain Stimulation (DBS) System
Description: For Stages 2 and 3 of this study, we intend to use the DBS system to treat patients with severe symptoms of chronic, treatment-refractory OCD by targeting stimulation to sites that have been determined to have therapeutic benefit during our SEEG Invasive Monitoring phase.
Study: NCT05182320

Intervention type: DEVICE
Intervention: OrthoPath
Description: unilateral TKA and THA patients using the BPMpathway rehabilitation sensor system

Intervention type: DEVICE
Intervention: Control
Description: unilateral TKA and THA patients not using the BPMpathway rehabilitation sensor system
Study: NCT06209541

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behavioral therapy (ICBT)
Description: All participants get treatment and are thus included in experimental groups, no matter the randomization result. It consists of eight treatment weeks with weekly support. The treatment format will differ between the four groups, depending on type of treatment content and type of support.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behavioral therapy (ICBT)
Description: All participants get treatment and are thus included in experimental groups, no matter the randomization result. It consists of eight treatment weeks with weekly support. The treatment format will differ between the four groups, depending on type of treatment content and type of support.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behavioral therapy (ICBT)
Description: All participants get treatment and are thus included in experimental groups, no matter the randomization result. It consists of eight treatment weeks with weekly support. The treatment format will differ between the four groups, depending on type of treatment content and type of support.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behavioral therapy (ICBT)
Description: All participants get treatment and are thus included in experimental groups, no matter the randomization result. It consists of eight treatment weeks with weekly support. The treatment format will differ between the four groups, depending on type of treatment content and type of support.
Study: NCT06288503

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hydrolysed Rice Protein Formula
Description: Infants randomised onto this arm will be taking the hydrolysed rice protein formula, with a minimum prescription of 30% of their energy requirements.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cow's Milk Based Extensively Hydrolysed Formula
Description: Infants randomised onto this arm will be taking the control product, with a minimum prescription of 30% of their energy requirements.
Study: NCT04781192

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Intra-Venous(IV) once every 28 days (approximately every 4 weeks \[q4w\])

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: Oral once per day, Days 1 - 21 every 28 days
Study: NCT05068089

Intervention type: PROCEDURE
Intervention: Nissen fundoplication
Description: Nissen fundoplication, numbers, reasons and length of hospitalizations, gastrointestinal symptoms and survival

Intervention type: BIOLOGICAL
Intervention: Enteral nutrition
Description: Type and switch of enteral nutrition formula (tube, PEG, PEJ)
Study: NCT06113926

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bystander Acknowledgment
Description: The experimenter said That is so messed up that they excluded you in the task. And honestly, I would say it was racist... acknowledgment of the participants experience, ...this shouldn't have happened, and I'm really sorry it did... an apology, and ...I'm going to talk to the primary investigators of the study to figure out how we can make sure that this won't happen to other people a plan of action.
Study: NCT04613960

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium sulfate
Description: MgSO4 (at a fixed daily dose of 64 mmol reconstituted in 0.9% saline) via continuous intravenous infusion for 14 days after onset

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: Placebo treatment
Study: NCT05492201

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally.
Study: NCT05808920

Intervention type: GENETIC
Intervention: Molecular Analyses
Description: Nucleic acid extraction, protein analysis. Tumour tissue, blood and saliva samples collected.
Study: NCT05634876

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UB-312 Injection
Description: UB-312, provided by Vaxxinity, contains 300 μg of p4573kb Drug Substance (synthetic peptide immunogen) formulated with CpG1 and Adju-Phos as a white, opaque, liquid suspension. The biological will be injected intramuscularly. The injection site will be the deltoid muscle.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UB-312 Injection
Description: UB-312, provided by Vaxxinity, contains 300 μg of p4573kb Drug Substance (synthetic peptide immunogen) formulated with CpG1 and Adju-Phos as a white, opaque, liquid suspension. The biological will be injected intramuscularly. The injection site will be the deltoid muscle.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UB-312 Injection
Description: UB-312, provided by Vaxxinity, contains 300 μg of p4573kb Drug Substance (synthetic peptide immunogen) formulated with CpG1 and Adju-Phos as a white, opaque, liquid suspension. The biological will be injected intramuscularly. The injection site will be the deltoid muscle.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UB-312 Injection
Description: UB-312, provided by Vaxxinity, contains 300 μg of p4573kb Drug Substance (synthetic peptide immunogen) formulated with CpG1 and Adju-Phos as a white, opaque, liquid suspension. The biological will be injected intramuscularly. The injection site will be the deltoid muscle.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo Injection
Description: Placebo will be injected intramuscularly. The injection site will be the deltoid muscle.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo Injection
Description: Placebo will be injected intramuscularly. The injection site will be the deltoid muscle.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo Injection
Description: Placebo will be injected intramuscularly. The injection site will be the deltoid muscle.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo Injection
Description: Placebo will be injected intramuscularly. The injection site will be the deltoid muscle.
Study: NCT06178939

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: control group
Description: The entire process is carried out according to Severance Hospital surgical protocols. The patients of control group will receive education from the research team about the importance of nutrition and exercise before and after surgery.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: intervention group
Description: For the intervention group, the entire process is carried out according to the Severance Hospital surgical protocol, and the research team provides education before surgery on the importance of nutrition and exercise before and after surgery. In addition, the cognitive training program developed by Rowan is taught with the goal of performing it for at least 10 hours before the surgery, it is conducted the training program after the surgery.
Study: NCT04976751

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Percutaneous electrical nerve stimulation treatment
Description: Using the percutaneous electrical nerve stimulation instrument to different points of the body
Study: NCT05771376

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Qigong exercise program
Description: The intervention group will perform a qigong exercise program online (via Zoom video conference) for 12 weeks under the supervision of two physiotherapists. The qigong exercise program had previously been videotaped by the researchers.~qigong exercise program includes: Preparation posture Prop up the sky by two improve trijiao Draw a bow on both sides like shooting a vulture Raise single arm up to regulate spleen Look back to treat five strains and seven impairments Shake the head and wag to expel Heart (Xin)-fire Pull toes with both hands to reinforce the kidney Clench one's fist and glare to increase strength Rise and fall on tiptoe sevan times to treat all diseases Ending posture. Qigong exercises will be performed 45 minutes twice in a week for 12 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home exercise program
Description: The home exercise program will include stretching for cervical, thoracic and lumbar flexibility, shoulder girdle, hamstring and erector spinal muscles, and strengthening exercises for abdominal, back, and proximal muscles.~Home exercises will be performed 45 minutes twice in a week for 12 weeks.
Study: NCT05858710

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DPPG2-TSL-DOX
Description: DPPG2-TSL-DOX is a thermosensitive liposomal formulation of doxorubicin.
Study: NCT06261502

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBD Oral Solution
Description: Participants will start with oral CBD dose of 5 mg/kg/day for two weeks and then increase to 10 mg/kg/day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBD Oral Solution
Description: Participants will start with oral CBD dose of 5 mg/kg/day for two weeks and then increase to 10 mg/kg/day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive a dose of a placebo composed of the inactive ingredients of CBD of the same volume as the CBD Oral Solution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive a dose of a placebo composed of the inactive ingredients of CBD of the same volume as the CBD Oral Solution.
Study: NCT06313775

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: bilateral orchiectomy
Description: Bilateral simple orchiectomy is the surgical removal of both testicles through an incision in the scrotum.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bilateral orchiectomy
Description: Bilateral simple orchiectomy is the surgical removal of both testicles through an incision in the scrotum.
Study: NCT04858243

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home-Based ART
Description: Community-based male-specific counseling followed by home-based ART initiation (or at any location that is convenient for participants) and home-based ART continuation for a 3-month period, followed by linkage to a local health facility for further ART continuation.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Facility-Based ART
Description: Community-based male-specific counseling followed by linkage to a local health facility for ART initiation and continuation.
Study: NCT05662631

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BioIntellisense BioSticker
Description: This study uses the BioIntellisense BioSticker for RPM, in combination with the BioSync mobile app on participants' mobile phones for data transmission, augmented by use of the BioHub as a backup transmission device. RPM monitoring of device data is accomplished through use of the AlertWatch software system.~BioSticker System TheBioSticker ® System is an FDA-approved remote monitoring wearable device intended for continuous collection of physiological data in home and healthcare settings. This includes heart rate, respiratory rate, skin temperature, estimated body temperature, frequency of severe cough episodes, activity level, sleep duration, body position, degree of incline while sleeping, step count, step symmetry, step strength, and on/off body times and other symptomatic and biometric data. Data are securely transmitted using AES-CTR 128 bit encryption via wireless connection from the device for storage, review, and further analysis.
Study: NCT05630209

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exablate
Description: Blood Brain Barrier Disruption (BBBD) via Exablate Type 2 system with microbubble resonators on the day of Doxorubicin infusion to treat DIPG brain tumors

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin infusion
Study: NCT05999032

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CASE in person version (High Intensity Package)
Description: Controlling Asthma in Schools Effectively (CASE) is a multi-level school-based asthma management program delivered by a Community Health Worker (CHW) that includes 1) staff training involving education on asthma management in school, 2) child-based asthma management education with an emphasis on control of symptoms in the school setting provided in a group setting during the school day, 3) caregiver education after school involving supporting children's asthma control in the school setting, 4), and provision of an Asthma Action Plan (AAP) to the school for child enrollees.
Study: NCT05347771

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab
Description: Dupilumab is a recombinant DNA-derived humanized IgG4ĸ monoclonal antibody that selectively binds to anti IL-4R monoclonal antibody (mAb).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The composition of the placebo for dupilumab is the same as the active study drug without the dupilumab.
Study: NCT04898868

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cord blood spontaneous drainage
Description: In women allocated to groups of cord blood spontaneous drainage, two clamps will placed at 4 finger breadths from the infant's abdomen and cut between two clamps after delivery of the baby. The clamp on the placental site will be removed and the drainage time and amount of cord blood to a measuring glass will be recored.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cord blood spontaneous drainage
Description: In women allocated to groups of cord blood spontaneous drainage, two clamps will placed at 4 finger breadths from the infant's abdomen and cut between two clamps after delivery of the baby. The clamp on the placental site will be removed and the drainage time and amount of cord blood to a measuring glass will be recored.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Umbilical cord miking
Description: In women allocated to groups of cord milking group, two clamps will placed at 4 finger breadths from the newborn's abdomen and cut between two clamps immediately after delivery of the baby. The clamp on the placental site will be removed, then the umbilical cord will be squeezed several times, 5 seconds between each squeezing, to collect cord blood in a measuring glass. The number of cord milking and the volume of blood collected will be recorded.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Umbilical cord miking
Description: In women allocated to groups of cord milking group, two clamps will placed at 4 finger breadths from the newborn's abdomen and cut between two clamps immediately after delivery of the baby. The clamp on the placental site will be removed, then the umbilical cord will be squeezed several times, 5 seconds between each squeezing, to collect cord blood in a measuring glass. The number of cord milking and the volume of blood collected will be recorded.
Study: NCT05795257

Intervention type: PROCEDURE
Intervention: Bronchoalveolar lavage
Description: Bronchoalveolar lavage in the middle lobe of the right lung and a mini-bronchoalveolar lavage in the upper and lower lobe of the right lung

Intervention type: PROCEDURE
Intervention: Bronchoalveolar lavage
Description: Bronchoalveolar lavage in the middle lobe of the right lung and a mini-bronchoalveolar lavage in the upper and lower lobe of the right lung
Study: NCT05605704

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: atherolive
Description: In each study population(Diabetic), the patient will be assigned to one of two treatments (atherolive or placebo) using a computer-generated randomization list (1: 1 allocation). The investigator who has the randomization code is not involved in other study procedures and does not interact with participants. The study drug (atherol) will be prescribed at a dose of 400 mg, once a day for 3 months. The placebo will be prescribed identically.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: atherolive
Description: In each study population(Diabetic), the patient will be assigned to one of two treatments (atherolive or placebo) using a computer-generated randomization list (1: 1 allocation). The investigator who has the randomization code is not involved in other study procedures and does not interact with participants. The study drug (atherol) will be prescribed at a dose of 400 mg, once a day for 3 months. The placebo will be prescribed identically.
Study: NCT06263725

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Restricted dietary protein
Description: Participants will be allocated to 5 week isocaloric restricted protein intake

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Restricted dietary protein
Description: Participants will be allocated to 5 week isocaloric restricted protein intake

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Habitual diet
Description: Participants will be follow their habitual, high protein intake

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Habitual diet
Description: Participants will be follow their habitual, high protein intake
Study: NCT05999032

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CASE-V remote version (Low Intensity Package)
Description: CASE-V, the low intensity version of CASE, includes similar child and caregiver-based asthma management education that is provided in a remote format with adaptation to integrate technological feature of Zoom. All CASE-V components (for staff, children, and parents) have been adapted to promote engagement (e.g., use of chat and polling function).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CASE and HARP in person (High Intensity package)
Description: Children with poorly controlled asthma will receive both the CASE and HARP programs. HARP is a home-visiting program that includes individualized asthma management education and strategies and supplies for environmental remediation. All 3 visits can be conducted by a CHW. The first includes a walk-through to identify triggers. Asthma education and self-management strategies are provided using a structured protocol and low-literacy flip-book (English or Spanish). Referrals and advocacy are offered to address asthma management barriers (e.g., communication with landlord/housing re: code violation). The 2nd and 3rd visits include delivery of supplies (e.g., HEPA vacuum, pest gels, mattress covers), instruction for use, review of AAP, and follow-up on environmental control recommendations provided during the 1st visit.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CASE-V and HARP-V remote version (Low Intensity package)
Description: HARP-V replicates the content delivered in HARP in a remote format. The first session includes a virtual walk-through in which the educator uses a structured script and checklist to guide the caregiver through the home and show specific components of the environment (e.g., carpeting, area under the kitchen sink, exhaust fan in bathroom) to identify asthma triggers. Asthma education and self-management strategies are provided using a structured protocol and slide overview based on the HARP flip-book. Supplies for environmental remediation are delivered prior to the 2nd visit. The 2nd and 3rd visit include instruction for use of supplies, review of AAP, and follow-up on recommendations and referrals.